Skip to main content
SpringerLink
Log in

Reply to: EEG-based model and antidepressant response

  • Matters Arising
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The Original Article was published on 14 December 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Scatterplot of the predicted change in HAMD17 score and the adjusted post-treatment HAMD17 score.

References

  1. Wu, W. et al. An electroencephalographic signature predicts antidepressant response in major depression. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0397-3 (2020).

  2. Nilsonne, G. & Harrell, F. Jr. EEG-based model and antidepressant response. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-00768-5 (2020).

  3. Chekroud, A. M. et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 3, 243–250 (2016).

    Article  Google Scholar 

  4. De Vries, Y. A. et al. Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. Br. J. Psychiatry 208, 515–521 (2016).

    Article  Google Scholar 

  5. Harrell Jr, F. E. & Slaughter, J. C. Biostatistics for Biomedical Research http://hbiostat.org/doc/bbr.pdf (2020).

  6. Bantis, L. Restricted cubic spline. MATLAB Centreal File Exchange. https://www.mathworks.com/matlabcentral/fileexchange/41241-restricted-cubic-spline (2020).

  7. Chandler, G. M. et al. Validation of the Massachusetts General Hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci. Therapeutics 16, 322–325 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA

    Wei Wu & Amit Etkin

  2. Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA

    Wei Wu & Amit Etkin

  3. Alto Neuroscience, Inc., Los Altos, CA, USA

    Wei Wu & Amit Etkin

  4. Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA

    Diego A. Pizzagall

  5. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Madhukar H. Trivedi

  6. O’Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Madhukar H. Trivedi

Authors
  1. Wei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego A. Pizzagall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Madhukar H. Trivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amit Etkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

W.W. and A.E. contributed to the analysis and interpretation of the data and the drafting and revision of the manuscript. D.A.P. and M.H.T. contributed to the drafting and revision of the manuscript.

Corresponding author

Correspondence to Amit Etkin.

Ethics declarations

Competing interests

W.W. receives salary and equity from Alto Neuroscience. Over the past 3 years, D.A.P. received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Otsuka and Takeda Pharmaceuticals as well as an honorarium from Alkermes. In addition, he has received stock options from BlackThorn Therapeutics. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. M.H.T. has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA and NIMH. A.E. receives salary and equity from Alto Neuroscience and options for equity from Mindstrong Health, Akili Interactive Labs and Sizung for unrelated work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, W., Pizzagall, D.A., Trivedi, M.H. et al. Reply to: EEG-based model and antidepressant response. Nat Biotechnol 39, 28–29 (2021). https://doi.org/10.1038/s41587-020-0738-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-0738-2

  • Springer Nature America, Inc.

Search

Navigation